CBL0137 is primarily investigated for its potential in cancer treatment. It works by targeting and disrupting the function of FACT (Facilitates Chromatin Transcription), a complex involved in DNA repair and transcription. By inhibiting FACT, CBL0137 can induce cancer cell death, particularly in tumors that are resistant to conventional therapies. This makes it a promising candidate for treating various cancers, including glioblastoma, melanoma, and pancreatic cancer. Additionally, its ability to sensitize cancer cells to other treatments, such as radiation and chemotherapy, enhances its therapeutic potential. Research is ongoing to explore its efficacy and safety in clinical trials.